Class 4 Caution in use- Simulect 10mg & 20mg powder and solvent for Solution for injection or infusion

Novartis Pharmaceuticals has informed the MHRA that the solvent (water for injections in ampoules) co-packed with the impacted batches of Simulect powder for injection, may contain glass fragments approximately 20 – 800 µm in size.

MHRA drug alert date: 16th May 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-novartis-pharmaceuticals-simulect-10mg-and-20mg-powder-and-solvent-for-solution-for-injection-or-infusion-el-23-a-slash-17?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=d08ff9e2-3185-4fca-b71c-1083f3f9bff0&utm_content=immediately

This is a caution in use only we are not accepting stock returns.

Further Information

For more information, medical or supply enquiries, please contact 01276 698370, or email medinfo.uk@novartis.com